Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-the-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform

Tevogen Bio announced positive topline results from its Proof-of-Concept clinical trial designed to evaluate the safety and feasibility of TVGN 489, the company’s first clinical product of its precision T Cell therapy platform, for the treatment of acute high-risk COVID-19 patients.